Today, Siemens Healthcare Diagnostics announces its entrance into a collaboration with Janssen Pharmaceutica NV to design, develop and commercialize a companion diagnostic test associated with an early-stage compound being developed by Janssen. This compound targets autoantibodies directed against the human β1-adrenergic receptor (β1-AR) that may contribute to the development of heart failure.
Under the agreement, Siemens will work with Janssen to design immunoassay-based companion diagnostic tests for use in Janssen's clinical studies. The Siemens Clinical Laboratory (SCL), an innovative and high-complexity testing laboratory designed to advance personalized medicine, will develop the clinical trial assay that will be used in Janssen’s clinical trials. In parallel, Siemens will develop and validate an in vitro diagnostic test as a companion diagnostic for the Janssen therapeutic product. The companion diagnostic test will be broadly commercialized on Siemens' central laboratory automated immunoassay systems.
Heart failure is generally a progressive disease characterized by the heart muscle’s inability to adequately pump oxygenated blood through the body. An estimated 23 million people around the world have been diagnosed with heart failure, a number that is projected to increase.¹ For most causes of heart failure, there is no known cure.
“Our relationship with Janssen marks an important next step in Siemens’ personalized medicine strategy,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. “As a leading clinical diagnostics company, with the tools and technologies to help define the future of patient care, we are looking forward to collaborating with Janssen and extending their position in cardiac therapies.”¹Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6. Launched in November 2011, “Agenda 2013” is the initiative of the Siemens Healthcare Sector to further strengthen its innovative power and competitiveness. Specific measures, which will be implemented by the end of 2013, have been defined in four fields of action: innovation, competitiveness, regional footprint, and people development.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV